Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.

Changing the way antibiotics are developed and accessed.

A public-health driven model to tackle AMR.

Our latest news and resources.

Protecting people from the rise and spread of drug-resistant infections.

Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.

GARDP reports.

Filter by

WHO PDP Cover Square 4 logos
Corporate

Strengthening WHO’s role in public health innovation: a PDP perspective

Read report
SECURE Report 2026 Thumbnail
Access to antibiotics

Understanding antibiotic access in the WHO African Region

Read report
PDP Advocacy paper
Corporate

GARDP joins seven other Product Development Partnerships in call for sustained EU investment in EDCTP

Global Health EDCTP3 | European Commission | European Vaccine Initiative (EVI) | FIND | Global Antibiotic R&D Partnership (GARDP) | IAVI | Medicines Development for Global Health | Medicines for Malaria Venture | TB Alliance

Read report
5by25 Cover
Corporate

GARDP’s 5 BY 25 Report: Laying the foundation for sustainable antibiotic R&D and access

Read report
India Meetingreport 2024
Access to antibiotics

Strengthening Antibiotic Access in India

Read report
Secure Report 2024 Thumbnail
Access to antibiotics

Policy and regulatory interventions to address antibiotic shortages in low and middle-income countries

World Health Organization, GARDP

Read report
Paediatricpolicypaper November2024
Neonatal sepsis

Survive and Thrive: Improving the Global AMR Response for Healthier Children and Newborns

Read report
Investmentcase Thumbnail
Corporate

Investing in GARDP 2024-2028

Read report
New York, NY, U.S.A. – Headquarters of the United Nations: United Nations is an intergovernmental organization that aims to maintain international peace and security.

Achieving a successful outcome to the UN High-Level Meeting on AMR: GARDP’s perspective

Read report